The relief you feel compared to month 2 is dramatic, suddenly this medication feels manageable, even easy
Oral GLP-1 treatment options may be considered for certain patients , depending on medical history, clinical evaluation, and provider determination
Its likely there will be several populations who can benefit from the drug once approved
The TRIUMPH-4 results, which we covered in our December 2025 GLP-1 practice update, are what triggered the current wave of patient and provider interest and with it, a dangerous underground market
It belongs to a class of agents known as multi-incretin receptor agonists, meaning it simultaneously targets three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
Side effects that linger: Persistent nausea, fatigue, or stomach discomfort beyond the adjustment period could mean you need a lower dose